Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
7 evidence topics · 5 sources
PSA progression criteria in clinical trials
“After decline from baseline: record time from start of therapy to first PSA increase that is ≥ 25% and ≥ 2 ng/mL above the nadir, and which is confirmed by a second value ≥ 3 weeks later (ie, a confirmed rising trend)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Soft-tissue and nodal progression criteria in clinical trials
“PCWG3 recommends that lymph nodes that were previously normal in size (< 1.0 cm) or pathologic in size must have grown by at least 5 mm in the short axis from baseline or nadir and be ≥ 1.0 cm in the short axis to be considered to have progressed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imaging and laboratory assessment in castration-resistant disease
Imaging cadence in clinical trials
“To minimize patient exposure to ineffective treatment, and to better assess the timing of the antitumor effects of an agent for which the optimal timing is not known, an 8- to 9-week assessment interval for the first 6 months and every 12 weeks thereafter is advised.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PSMA PET imaging before PSMA-targeted radioligand therapy
“Documentation of PSMA expression in metastatic sites is required prior to the initiation of RLT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The diagnostic accuracy of PSMA-ligand PET/CT for bone assessment was superior to that of bone scan” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Germline and somatic genomic testing
“Patients with metastatic prostate cancer should undergo both germline and somatic DNA sequencing using panel-based assays. These tests can guide the use of poly(ADP-ribose) polymerase inhibitors, which have a survival benefit in metastatic castration-resistant prostate cancer.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote